Polyrizon Ltd., a biotechnology company focused on intranasal products, has announced promising preclinical results for its proprietary intranasal naloxone hydrogel formulation. The research demonstrated that the hydrogel offers significantly enhanced tissue retention compared to a currently marketed intranasal naloxone product, without compromising the rapid drug permeation required for emergency opioid overdose treatment. The results, which include stability, mucoadhesion, and permeability studies, reinforce the potential of Polyrizon's Trap & Target™ technology to deliver improved performance in real-world scenarios. The company has already completed these studies and announced the findings, positioning the product for further development.